Trump fingers Robert F. Kennedy Jr. to lead the HHS, lupus and ATTR-CM dominate headlines this week, bluebird bio has a cash gap to leap and RegenxBio eyes Sarepta in Duchenne muscular dystrophy.

- VY1706 is the fifth neuro gene therapy development candidate nominated leveraging Voyager’s IV-delivered, CNS-penetrant TRACER capsids - ...

Belite Bio's, Tinlarebant, targets eye diseases STGD1 and GA, showing promising results but with delayed phase 3 trial data.

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...

On Monday, Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) presented long-term safety and efficacy results from the Phase 1 study ...

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...

Researchers described a promising new approach for using gene therapy to treat sickle cell disease in the journal Human Gene ...

Sana Biotechnology, Inc.'s stock has dropped, but with pipeline focus and upcoming trial data, its prospects remain mixed ...

The key benefit of zerlasiran’s approach is its ability to directly target and silence the gene responsible for Lp(a) ...

Metagenomi is preparing to initiate IND-enabling activities that seek to support MGX-001’s transition from preclinical to ...

Researchers at Children's Hospital of Philadelphia (CHOP) announced encouraging results from the first ever gene therapy ...

The FDA has released a draft of new guidance addressing common FAQs about the development of potential CGT treatments.